English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 17 April 2024, 08:11 HKT/SGT
Share:
    

Source: Kaplan Fox & Kilsheimer LLP
ZOETIS (ZTS): Kaplan Fox & Kilsheimer LLP Investigates Zoetis and Encourages Investors with Losses to Contact the Firm

NEW YORK, Apr 17, 2024 - (NewMediaWire) - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Zoetis Inc.  (“Zoetis” or the “Company”) (NYSE: ZTS).  Click here to join the investigationhttps://www.kaplanfox.com/join-a-case/ 

If you invested in Zoetis and would like to discuss our investigation, please click here https://www.kaplanfox.com/join-a-case/ or contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

On April 12, 2024, The Wall Street Journal published an article concerning Zoetis reporting that health regulators in the U.S. and Europe have received thousands of complaints about Zoetis’ arthritis drugs for pets - Librela for dogs and Solensia for cats -  due to negative side effects.  The article also reports that regulators in the U.S. and Europe are conducting reviews of the drugs. 

Following this news, the price of Zoetis shares declined by $12.75 per share, or 7.84%, to close at $149.98 per share on April 12, 2024.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.  With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.  Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.  For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you have any questions about this investigation, please contact:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
E-mail: pmayer@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax:  (415) 772-4707
E-mail: lking@kaplanfox.com



Topic: Press release summary
Source: Kaplan Fox & Kilsheimer LLP

Sectors: Legal & Compliance
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 
Kaplan Fox & Kilsheimer LLP Links

http://www.kaplanfox.com

https://www.facebook.com/KaplanFoxLawFirm

https://twitter.com/kaplanfoxlaw

https://www.linkedin.com/company/kaplan-fox-&-kilsheimer-llp/

Kaplan Fox & Kilsheimer LLP Related News
July 11, 2024 08:00 HKT/SGT
DRIL-QUIP (NYSE: DRQ): Kaplan Fox & Kilsheimer LLP Investigates Dril-Quip Following Disclosure of $67 Million of Misclassified Inventory Write-Downs
July 10, 2024 08:00 HKT/SGT
DRIL-QUIP (NYSE: DRQ): Investigation of Dril-Quip for Potential Securities Law Violations
June 20, 2024 20:32 HKT/SGT
Scotts Miracle-Gro (SMG) Investor Alert: Kaplan Fox & Kilsheimer LLP Encourages Investors to Contact the Firm in Scotts Securities Fraud Class Action
June 19, 2024 11:43 HKT/SGT
Kaplan Fox Files Class Action to Recover Losses for Investors Who Purchased Common Stock of Inari Medical, Inc. (NasdaqGS: NARI) for an Expanded Class Period - March 10, 2021 through February 28, 2024
June 19, 2024 07:00 HKT/SGT
SCOTTS MIRACLE-GRO (SMG) ALERT: Kaplan Fox & Kilsheimer LLP Reminds Investors of Important August 5, 2024 Lead Plaintiff Deadline in Securities Fraud Class Action
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575